Related Experiment Videos
Melatonin and mammary pathological growth.
1Department of Physiology and Pharmacology, University of Cantabria, Santander, 39011, Spain.
Frontiers in Neuroendocrinology
|April 15, 2000
Summary
Melatonin, a pineal gland hormone, shows promise in fighting mammary cancer. Studies indicate melatonin can slow tumor growth and reduce incidence in animal models and human cell lines.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- The pineal gland and its hormone melatonin are investigated for their influence on mammary cancer.
- Melatonin's potential role stems from its regulation of hormones involved in mammary gland development and hormone-dependent tumor growth.
Purpose of the Study:
- To review the current understanding of melatonin's role in mammary cancer development and progression.
- To evaluate the evidence for melatonin's direct and indirect antitumoral effects.
Main Methods:
- Review of in vivo studies using animal models of chemically induced mammary tumors.
- Analysis of in vitro studies using MCF-7 human breast cancer cells.
Main Results:
- In vivo: Pineal gland activation or melatonin administration reduced mammary tumor incidence, growth rate, and latency.
- In vitro: Melatonin inhibited proliferation and invasiveness of MCF-7 cells at physiological doses.
- Melatonin exhibits antioxidant and immunoenhancing properties that may contribute to its antitumoral effects.
Conclusions:
- Melatonin demonstrates significant antitumoral activity against mammary cancer in both in vivo and in vitro models.
- Further clinical research is warranted to explore melatonin's therapeutic potential in breast cancer treatment.